Friday, April 5th, 2013 - Vital Therapies, Inc.

SAN DIEGO, CA -- (Marketwired) -- Vital Therapies, Inc., a development-stage biotechnology company focused on developing the first bio-artificial liver for life-threatening acute liver failure, today announced enrollment of the first patient in a phase 3 trial designated VTI-208. The patient was enrolled at Emory University Hospital in Atlanta, Georgia last month.

VTI-208 is a randomized, open-label, multicenter, controlled trial comparing the company's investigational bio- artificial liver support system, ELAD® plus standard-of-care, versus standard-of-care alone in 200 patients with alcohol-induced liver decompensation. The primary endpoint is ninety-day overall survival and the safety and tolerability of the two treatment groups will also be compared. Patients will also be followed for 5 years in an extension protocol that will gather further survival, transplant, and other health data. Several other centers that will participate in the study are also already open for patient enrollment, and the company anticipates the study to open up 25 clinical sites by year-end.

Dr. Ram Subramanian, a transplant hepatologist and intensivist at Emory University Hospital and principal investigator, said, "We are very excited to be participating in the largest-ever clinical research trial evaluating artificial liver support. Given the lack of effective therapies in this area, this is an important milestone as this clinical program, if successful, may eventually open up much-needed options for these critically ill patients."

The company received Scientific Advice from the European Medicines Agency (EMA) and U.S Food and Drug Administration (FDA) on the design and planned analysis of the VTI-208 trial. The study will be conducted at sites in the United States, Europe, and Australia. For information about enrolling in the study, please visit www.clinicaltrials.gov.

Later this year, Vital Therapies plans to initiate two other randomized, controlled Phase 3 clinical trials: VTI-210, in patients with biopsy-proven acute alcoholic hepatitis; and VTI-212, a trial in patients with fulminant hepatic failure.

Dr. Terry Winters, Vital Therapies, Inc.'s Chief Executive Officer and Co-Chairman, said, "With the benefit of a large private financing which recently closed, we are now implementing our Phase 3 program. We are grateful to our investors for their generous support, and to our investigators for their interest in evaluating our promising new investigational therapy, ELAD."

Contact Profile

Vital Therapies, Inc.


Vital Therapies, Inc. is a private development-stage biotechnology company based in San Diego, California. The company is developing ELAD, an investigational extracorporeal liver support system which has been studied in seven clinical trials in US, EU and Asia. Moreover, a US/EU phase 3 trial plan to support potential BLA and MAA marketing approval has received written guidance from FDA and EMA. Vital Therapies retains all rights to ELAD and has no corporate partners.
Terry Winters
P: 858-673-6840
M: -
W: www.clinicaltrials.gov/

Keywords

Vital Therapies, Inc., Alcohol-Induced Liver Decompensation

Categories

Sharing

More Formats